Last reviewed · How we verify
active FMT
At a glance
| Generic name | active FMT |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis (NA)
- FMT Capsules for rCDI (PHASE3)
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1, PHASE2)
- Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis (NA)
- Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis (PHASE3)
- Fecal Microbiota Transplantation in Children With ASD (NA)
- Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis (PHASE1)
- The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- active FMT CI brief — competitive landscape report
- active FMT updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI